Pfizer Inc. (PFE) on Thursday said it received marketing authorization in U.K. for its atopic dermatitis drug, Cibinqo.
Cibinqo (abrocitinib), a Janus kinase 1 (JAK1) inhibitor, has been authorized by UK's Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of moderate to severe atopic dermatitis in adults and adolescents aged 12 years and over, who are candidates for systemic therapy.
Atopic dermatitis is a chronic skin condition characterized by dry, itchy skin.
Regulatory applications for abrocitinib have been submitted to countries around the world for review, including the United States, Australia, Japan, and the European Union, Pfizer said.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.